DAWN

NEUTRALM&A

Day One Biopharmaceuticals, Inc

2026-04-20

Price

$21.48

+0.05%

Score12.2Priority

Signals7/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 6

Volume1.0xvs 20d avg

Analysis

DAWN's price action is entirely dictated by its pending acquisition by Servier Pharmaceuticals for $21.50 per share in cash. The stock's SURGE and QUIET_STORM signals perfectly capture the initial 65% buyout pop in March, followed by the current ultra-low volatility (2.0% annualized) merger arbitrage consolidation just pennies below the offer price. The prevailing RISK_ON macro regime, characterized by exceptionally tight corporate credit spreads (0.80% OAS), provides high conviction that financing conditions remain pristine and the deal will close smoothly in Q2 2026.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEWEAK FINISH

Key Takeaways

DAWN is currently trading as a pure merger arbitrage play against Servier's $21.50 all-cash tender offer.
The ultra-low 2.0% realized volatility and QUIET_STORM signal reflect the market pricing in a near-100% probability of deal completion.
Key risk remains procedural roadblocks such as shareholder litigation or antitrust delays, though major shareholders have already tendered their stakes.

← Back to 2026-04-20 View Full DAWN History →Yahoo Finance &nearr;